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Abstract  36 
Objective: To analyze late urinary toxicity after prostate cancer radiotherapy (RT): 37 
symptom description and identification of patient characteristics or treatment 38 
parameters allowing for the generation of nomograms. 39 
Methods: 965 patients underwent RT in seventeen French centers for localized 40 
prostate cancer. Median total dose was 70 Gy (range, 65-80 Gy), using different 41 
fractionations (2 or 2.5 Gy/day) and techniques. Late urinary toxicity and the 42 
corresponding symptoms (urinary frequency, incontinence, Dysuria/decreased 43 
stream and hematuria) were prospectively assessed in half of the patients using the 44 
LENTSOMA classification. Univariate and multivariate Cox regression models 45 
addressed patient or treatment-related predictors of late urinary toxicity (! grade 2). 46 
Nomograms were built up and their performance was assessed. 47 
Results : The median follow-up was 61 months. The 5-year (!grade 2) global urinary 48 
toxicity, urinary frequency, hematuria, dysuria and urinary incontinence rates were: 49 
15%, 10%, 5%, 3% and 1%, respectively. The 5-year (! grade 3) urinary toxicity rate 50 
was 3%. The following parameters significantly increased the 5 year risk of global 51 
urinary toxicity (! grade 2): anticoagulant treatment (RR=2.35), total dose (RR=1.09), 52 
age (RR=1.06). Urinary frequency was increased by the total dose (RR=1.07) and 53 
diabetes (RR=4). Hematuria was increased by anticoagulant treatment (RR=2.9). 54 
Dysuria was increased by the total dose (RR=1.1). Corresponding nomograms and 55 
their calibration plots were generated. Nomogram performance should be validated 56 
with external data. 57 
Conclusions: The first nomograms to predict late urinary toxicity but also specific 58 
urinary symptoms after prostate RT were generated, contributing to prostate cancer 59 
treatment decision. 60 
 = 
1. Introduction 61 
 62 
Radical prostatectomy (RP) and radiotherapy (RT) are cornerstones of localized 63 
prostate cancer treatment, leading to relatively similar results in terms of local control 64 
1. However, the side effects of both are different, mainly concerning the urinary 65 
adverse events. If the intensity of this toxicity after RT is relatively well-reported in the 66 
literature, the description of the symptoms corresponding to this toxicity is often 67 
limited. Moreover, the patient and/or treatment factors related to each of the side 68 
effects are not well known. Their identification is crucial. These factors could be used 69 
to generate urinary toxicity predictive tools (like nomograms), to guide the physician 70 
in deciding the treatment and to inform the patient, in this context of different 71 
therapeutic alternatives. To identify which radiation parameters increase toxicity is 72 
essential in understand how to decrease toxicity, in particular due to new highly-73 
conformal radiotherapy techniques, such as Intensity Modulated Radiation Therapy 74 
(IMRT) and Image Guided Radiation Therapy (IGRT).  75 
These new techniques allow for an increase of the dose in the prostate considering 76 
the strong dose-effect relationship for local control 2, while limiting the dose in the 77 
bladder and the rectum. Their part in decreasing urinary toxicity has not, however, 78 
been clearly shown. If the relationship between dose-volume and toxicity has been 79 
consistently demonstrated for the rectum, it remains unclear for the bladder 3, 4. 80 
Moreover, hypofractionated RT may be more efficient in eradicating prostate 81 
adenocarcinoma, but the impact of such modified fractionation on toxicity has not 82 
been well-established.  83 
If nomograms have already been published to predict rectal bleeding and the risk of 84 
fecal incontinence 5, 6, to our knowledge no tools have as yet been developed to 85 
 = 
predict urinary toxicity. 86 
We thus analyzed a large group of patients having received prostate cancer RT using 87 
different radiation techniques, total doses and fractionations, to accurately quantify 88 
and describe late urinary toxicity, identify related risk factors and propose 89 
nomograms.  90 
 91 
2. Material and methods 92 
 93 
2.1. Patient inclusion criteria 94 
 95 
Records from 965 patients who received definitive radiotherapy for localized prostate 96 
adenocarcinoma were analyzed. Data were prospectively collected from 470 patients 97 
treated in 17 French institutions within two randomized studies: GETUG 06 98 
(comparing 70 Gy to 80 Gy) 7 and STIC-IGRT (testing IGRT) 8, and retrospectively 99 
from 495 patients treated in two of them. All patients had a biopsy-proven 100 
adenocarcinoma of the prostate. Pretreatment workup included a CT scan and a 101 
bone scan.  102 
 103 
2.2. Patient and tumor characteristics  104 
 105 
The following data were extracted from each randomized database: age, medical and 106 
surgical history (prior abdominal surgery, prior transurethral resection of prostate, 107 
anticoagulant treatment, diabetes, hypertension, coronary insufficiency) and tumor 108 
characteristics (T stage, Gleason score, pretreatment PSA). Patients were staged by 109 
digital rectal examination according to the 1992 American Joint Committee on 110 
 = 
Cancer staging system 9. Patients were classified into the three prognostic risk 111 
groups defined by D’Amico 1. Patient and tumor characteristics are presented in 112 
Table 1. 113 
 114 
2.3. Treatment characteristics 115 
 116 
The target volume comprised the prostate only in the low risk group (16%), the 117 
prostate and the seminal vesicles in the other risk groups. The pelvic lymph nodes 118 
were not treated in the two randomized studies, but may have been treated for high 119 
risk patients of the two institutions (not treated in the randomized study) (9%). The 120 
median total dose of the prostate was 70 Gy (ranging from 65 Gy to 80 Gy), the 121 
seminal vesicles receiving 46 Gy, and the pelvic lymph nodes also 46 Gy, if treated. 122 
Dose per fraction was 2 Gy/day, 5 fractions/week for 69% of patients, or 2.5 Gy/day, 123 
4 fractions/week for 31% of patients. 124 
The radiation technique was 3D conformational for the vast majority of patients (85%) 125 
and 2D for 15% of the patients, depending on the treatment period. Intensity 126 
Modulated RT (IMRT) and Image Guided RT (IGRT) have been more recently used 127 
in patients receiving 80 Gy. Among the 41% of the patients having received 80 Gy, 128 
the technique was a standard 3D conformal RT for 63%, IMRT only for 18% and 129 
IMRT combined with IGRT in 19%. 130 
The 3D radiation technique was carried out following the French GETUG group 131 
recommendations, as previously reported 7. Patients underwent simulation and 132 
treatment in the supine position. Target volume and organs at risk (bladder, rectum 133 
and femoral heads) were delineated on CT slices. A bladder wall was generated with 134 
a thickness of 7 mm from the external manually-delineated bladder contour according 135 
 = 
GETUG recommandations. The planning target volume (PTV) was calculated by 136 
adding a 10-mm margin in all directions except in the posterior where a 5-mm margin 137 
was considered. The dose-volume histogram had to respect the GETUG constraints 138 
7. The following bladder dosimetric data were analyzed: volume of the bladder wall, 139 
Dmax (maximal dose received in the bladder), D25 (minimal dose received in 25% of 140 
the bladder wall) and D50 (minimal dose received in 50% of the bladder wall). 141 
Androgen deprivation therapy was given to 23% of the patients, all presenting a high 142 
risk cancer. 143 
Details of treatment characteristics are presented in Table 1. 144 
 145 
2.4. Follow up and toxicity grading 146 
 147 
According to the protocol of surveillance, patients were evaluated every three months 148 
for a year and every 6 months thereafter Late urinary toxicity was defined as events 149 
occurring more than six months after the beginning of RT. To determine the severity 150 
and incidence of main late urinary complaints, records were prospectively extracted 151 
from trials database or retrospectively from physicians’ reports, at each follow-up 152 
visit. Urinary complaints were classified according to the LENTSOMA morbidity 153 
scoring system into four categories of symptoms: urinary frequency, dysuria, 154 
incontinence and hematuria  (Table 2). Dysuria and decreased stream were 155 
considered as a single symptom. The analyses were performed for late urinary 156 
toxicity and for each of the symptoms, all being considered if ! grade 2. 157 
 158 
2.5.  Statistical analysis 159 
 160 
 = 
The impact of the following parameters on late urinary toxicity (! grade 2) was tested 161 
at the 5-years mark: 162 
- Patient parameters:  age, diabetes (types 1 and 2), anticoagulant treatment 163 
(vitamin K antagonist or antiplatelet drug), prior abdominal or pelvic surgery, 164 
prior transurethral resection of prostate, hypertension, coronary insufficiency; 165 
- Tumor parameters: Gleason Score, T stage, prognostic group (D'amico); 166 
- Treatment parameters: RT technique (2D technique, 3DConformational 167 
technique, with or without IMRT/IGRT), total dose and fractionation, target 168 
volume, dosimetric bladder parameters (volume of the bladder wall, maximal 169 
dose, D25, D50) and androgen deprivation.  170 
The data-recording modality (prospective versus retrospective collection) was 171 
verified as having no significant impact on the risk of toxicity.  172 
The Kaplan-Meier method was used to calculate cumulative incidences of late 173 
urinary toxicity events (! grade 2). The differences between the survival curves 174 
were assessed using the log-rank test. Relationships between late urinary toxicity 175 
and patient, tumor or treatment parameters were first analyzed using Cox 176 
proportional hazard regression at univariate level. Multivariate analyses, including 177 
covariates statistically significant in univariate analysis, were carried out using the 178 
Cox proportional hazards model. The 5-year late urinary toxicity events were 179 
analyzed using logistic regression at univariate and multivariate levels. A p-value 180 
" 0.05 was considered statistically significant. Nomograms to predict 5-year late 181 
urinary toxicity and specific symptoms were built up according to the logistic 182 
model. To assess nomogram performance, a nonparametric fit of the predicted 183 
probability as regards the actual observed probability was made for each 184 
nomogram.  The analyses were performed using the SPSS V18 (Chicago, IL) and 185 
 = 
R with the rms package. Non-parametric tests were used to compare the 186 
distribution of the parameters between different groups of treatment. 187 
 188 
3. Results 189 
 190 
The median follow-up was 61 months (range 6-206). 191 
 192 
3.1. Late urinary toxicity: global quantification and symptom description 193 
 194 
Among the 965 patients, 183 events of late urinary toxicity grade 2 or greater were 195 
reported. Among them, only 14 % were toxicity grade 3 or 4. Ninety-two (50%) 196 
corresponded to an increase in urinary frequency, 36 (20%) to dysuria, and 48 (26%) 197 
to hematuria. Only seven consisted of urinary incontinence grade 2 or greater. The 5-198 
year and 10-year rates of grade 2 or higher urinary toxicity, urinary frequency, 199 
hematuria, dysuria and urinary incontinence were: 15% (95%CI:12%-18%) and 24% 200 
(95%CI:19%-29%), 10% (95%CI: 8%-12%) and 15% (95%CI:11%-19%), 5% (95% 201 
CI: 4-6%) and 8% (95%CI:5%-11%), 3% (95%CI: 2%-4%) and 8% (95%CI:4%-12%), 202 
and 1% (95%CI: 0%-2%) and 2% (95%CI:0%-4%), respectively. Figure 1 presents 203 
cumulative incidence of global late urinary toxicity and the corresponding symptoms 204 
(! grade 2).The 5 and 10-year rates of grade 3 or higher global urinary toxicity were 205 
3% (95%CI: 2%-4%) and 7% (95%CI:5%-9%). 206 
 207 
3.2. Nomograms to predict five-year late toxicity 208 
 209 
In multivariate analysis, the following pre-planning parameters significantly positive 210 
 = 
associated to the 5-year risk of urinary toxicity: anticoagulant treatment (RR=2.35), 211 
total dose (RR=1.09),  age (RR=1.06), D25 (RR=1.03), and Dmax (RR=1.1) received 212 
by the bladder (Table 3). Nomogram including pre-treament factors to predict 5-year 213 
risk of global late urinary toxicity (and its calibration plot) is presented in Figure 2. 214 
The 5-year risk of urinary frequency was related to total dose (RR=1.07) and 215 
diabetes (RR=4). For dysuria, the total dose was the only significant factor (RR=1.1) 216 
(Table 3). Figures 3 and 4 present nomograms to predict the 5-year risk of these 217 
urinary symptoms. The 5-year risk of hematuria was significantly increased by 218 
anticoagulant treatment (RR = 2.9) 219 
 220 
4. Discussion 221 
We showed that the incidence of late urinary toxicity symptoms continuously 222 
increases after RT, reaching a rate of 24% and 7% at 10 years, for more than grade 223 
2 and grade 3 urinary toxicity, respectively. These rates appear relatively similar to 224 
those previously observed after RT 7. Urinary toxicity events may occur late after RT, 225 
later than those observed for late gastro-intestinal toxicity which generally reaches a 226 
plateau at three years after RT 10. A longer follow-up is consequently required to 227 
properly estimate late urinary toxicity 10. Comparing the risk of urinary toxicity after 228 
different treatments should therefore carefully consider the same follow-up. Late 229 
urinary toxicity symptoms are mainly characterized by urinary frequency (50% of all 230 
events) and, to a lesser extent, by dysuria and hematuria. Incontinence is very rare 231 
(<2% at 10 years).  232 
We identified age, diabetes and anticoagulant treatment as factors increasing the risk 233 
of late urinary toxicity by multivariate analysis. Diabetes has already been reported 234 
as a strong predictor of late urinary toxicity in prostate cancer radiotherapy 11. The 235 
 = 
fact that anticoagulation or antiplatelet agents increase the risk of late urinary toxicity 236 
after prostate cancer radiotherapy has rarely been reported, even if this association 237 
concerns the risk of late rectal toxicity 12, 13. However, anticoagulation has been 238 
already associated with gross hematuria in the whole population and could be an 239 
independent risk factor of urinary complaints whatever a radiation is performed. Age 240 
and diabetes have been previously associated with urinary side effects after radical 241 
prostatectomy, especially urinary incontinence 14, 15. Thus, their implications in urinary 242 
toxicity after RT should not be underestimated in treatment decision. 243 
We found a strong dose-effect relationship in urinary toxicity (global toxicity, urinary 244 
frequency and dysuria). Most of the randomized studies comparing a “standard” dose 245 
(68 to 70 Gy) to a higher one (76 to 80 Gy) did not demonstrate such a significant 246 
increase in late urinary toxicity 16-19. However, in a large group of patients who 247 
received a dose escalation with 3D-CRT/IMRT, Zelefsky et al reported a significant 248 
increase of genitourinary (GU) toxicities after 10 years in patients who received 249 
higher doses 20. More recently, the GETUG 06 randomized trial reported such an 250 
increase, when escalating the dose from 70 Gy to 80 Gy 7. These differences can be 251 
explained by several reasons. The first one is the lack of follow-up. Indeed, the initial 252 
MDACC report that compared 78Gy to 70Gy did not show a significant difference in 253 
late GI toxicity, while it was found with a longer follow-up16. Secondly, studies might 254 
be different in terms of their treatment scheme (dose, target volume, technique), 255 
patient characteristics and grading scale. Finally, urinary toxicity might be more 256 
related to patient risk factors than dose parameters. The lack of correlation between 257 
dose distribution (dose-volume histogram) and urinary toxicity may also be due to the 258 
large bladder volume variation occurring at the planning stage and at the different 259 
 = 
fractions, so that the planned dose distribution does not represent the actual 260 
delivered dose to the bladder.   261 
A moderate hypofractionned schedule (2.5 Gy/fr) in our series did not increase late 262 
urinary toxicity. These results are concordant with contemporary studies 21 and 263 
emphasize the interest of hypofractionated schedule in prostate cancer radiotherapy. 264 
IMRT and IGRT aim at increasing local control by allowing dose escalation, while 265 
reducing toxicity by sparing normal surrounding tissues. Compared to "standard" 3D 266 
conformal technique, IMRT clearly reduces the risk of long-term rectal toxicity and 267 
bowel dysfunction 20, 22, 23. However, IMRT fails to decrease late urinary toxicity in 268 
most studies, as in the present one. Late urinary toxicity could even be partly due to 269 
prostatic urethra lesions 24, and modern techniques such as IMRT combined with 270 
IGRT still do not allow for the preservation of this area. A recent non-randomized 271 
study of Zelefsky et al reported however that, with a median follow-up of 2.8 years 272 
and a high dose (86.4 Gy) delivered to the prostate by IMRT, patients treated with 273 
IGRT (using fiducials) experienced significantly less urinary toxicity than non-IGRT 274 
treated patients25.  275 
Based on this predictive factors, we propose the first nomograms to predict late 276 
urinary toxicity after radiation therapy. Indeed, many treatments now provide long 277 
term survival and the decision of the patient concerning his own treatment  is mainly 278 
based on expected side effects. These nomograms have been built up according to 279 
the pre-treatment parameters, available before any CT simulation, in order to help 280 
physician and patient in the decision concerning the different prostate cancer 281 
treatments. Consequently, we believe that the corresponding nomograms concerning 282 
toxicity after radical prostatectomy should be proposed. 283 
One limitation of our study is that both prospective and retrospective data (from 2 284 
 = 
institutions) were used to assess our nomograms. However, the effect of data being 285 
retrospectively collected was not found to significantly impact on toxicity risk. 286 
Furthermore, a large number of patients was necessary to identify a maximum 287 
number of reliable toxicity predictors. Finally, nomogram performance has been 288 
validated within our series but should be also confirmed using external data. 289 
 290 
5. Conclusions 291 
 292 
We were able to identify several parameters increasing the risk of urinary toxicity 293 
after prostate cancer radiotherapy. The first nomograms to predict global late urinary 294 
toxicity and corresponding symptoms were generated, resulting in new tools for 295 
patient management and treatment decision, particularly between RT and surgery. 296 
297 
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Figure legends 412 
 413 
 414 
Figure1: Incidence of global and by symptoms late urinary toxicity (!grade 2) 415 
according to LENTSOMA classification 416 
 417 
 = 
 418 
Figure 2: Five-year risk of global late urinary toxicity grade ! 2 : nomogram and 419 
calibration plot  420 
Calibration plot assessing the nomogram performance by a nonparametric fit of the 421 
 = 
predicted probability versus the actual observed probability. 422 
 423 
 424 
Figure 3: Five-year risk of urinary frequency grade ! 2: nomogram and 425 
 = 
calibration plot 426 
Calibration plot assessing the nomogram performance by a nonparametric fit of the 427 
predicted probability versus the actual observed probability. 428 
 429 
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Figure 4: Five-year risk of dysuria grade ! 2: nomogram and calibration plot 430 
Calibration plot assessing the nomogram performance by a nonparametric fit of the 431 
predicted probability versus the actual observed probability. 432 
 433 
434 
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Table 1: Patient, tumor and treatment characteristics 435 
 436 
Patient characteristics 
Number of patients 965 
Mean age,.yr (range) 68 (45-83) 
Diabetes* 7% 
Anticoagulant treatment** 21% 
Prior abdominal or pelvic surgery  34% 
Prior transuretral resection of prostate 6% 
Hypertension 19% 
Coronary insufficiency 9% 
Tumor characteristics 
PSA, ng/ml (range) 15 (0-133) 
Gleason Score 
<7 53% 
7 38% 
>7 9% 
T stage 
T1 25% 
T2 62% 
T3 13% 
Prognostic group of risk 
(D'amico) : 
Low 18% 
Intermediate 51% 
High 31% 
Treatment characteristics 
Radiotherapy technique 
2D Technique 15% 
« Standard » 3D Conformational (without IMRT) 66% 
IMRT (without IGRT) 7% 
IGRT (with IMRT) 12% 
Prescribed dose and fractionation 
65 Gy 2.5Gy. 4/w 15% 
70 Gy 
2.5Gy. 4/w 16% 
2Gy. 5/w 28% 
80Gy  2Gy. 5/w 41% 
Target volume 
Prostate only 16% 
Prostate + Seminal vesicles 75% 
Prostate + Seminal vesicles + Pelvic lymph nodes 9% 
 = 
Dosimetric parameters 
Bladder 
(wall***) 
Volume (cc) +/- SD 70,7 +/- 39,5 
Dmax(Gy) +/- SD 75,8 +/- 4,7 
D25 (Gy) +/- SD 64,8 +/- 11,6 
D50 (Gy) +/- SD 43,1 +/- 15,2 
Target 
PTV prostate and SV (cc) +/- SD 234,5 +/- 60,9 
PTV prostate only (cc) +/- SD 174,2 +/- 55,6 
V95 (%)+/- SD 93,1 +/- 10,8 
Androgen deprivation (concomitant and adjuvant) 23% 
 437 
 438 
Yr: year, * type 1 or 2, ** vitamin K antagonist and antiplatelet drugs, W: week, SD: 439 
Standard Deviation, ***thickness of bladder wall = 7mm, Dmax: maximum dose, D25: 440 
minimal dose received in 25% of the bladder wall volume, D50: minimal dose 441 
received in 50% of the bladder wall volume, PTV: planning target volume, V95: 442 
volume of the prostate-PTV (in %) receiving 95% of the prescribed dose. 443 
  26 
Table 2: LENTSOMA grading scale (Urinary symptoms) 
 grade I grade  II grade III grade IV 
Subjective     
Dysuria occasional and minimal intermittent and tolerable persistent and intense refractory and 
excruciating 
Decreased 
stream 
occasionally weak intermittent persistent but incomplete 
obstruction 
complete obstruction 
Frequency 3–4-h intervals (6–8/day) 2–3-h intervals (9–12/day) 1–2-h intervals (13–24/day) hourly (>24/day) 
Hematuria occasional intermittent persistent with clot  refractory 
Incontinence < weekly episodes < daily episodes pads/undergarments/day refractory 
Management     
Dysuria occasional, nonnarcotic regular nonnarcotic regular narcotic surgical intervention 
Decreased 
stream 
 < 1/day self catheterization dilatation or TUR, > 1/day self 
catheterization 
permanent catheter, 
surgical intervention 
Frequency  occasional antispasmodic regular narcotic cystectomy 
Hematuria  alkalization iron therapy single transfusion or 
cauterization 
frequent transfusions or 
coagulations  
surgical intervention 
Incontinence occasional use of 
incontinence pads 
intermittent use of 
incontinence pads 
regular use of incontinence 
pads or self 
catheterization 
permanent catheter 
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Table 3: Patient, tumor and treatment factors related to five year risk of late urinary toxicity and corresponding symptoms 
(multivariate regression logistic analysis) 
Factors 
Late urinary toxicity Urinary frequency Hematuria Dysuria 
RR (95.0% CI) 
p 
value RR (95.0% CI) 
p 
value RR (95.0% CI) 
p 
value RR (95.0% CI) 
p 
value 
Anticoagulant 
treatment 
2.35 (1.33 - 4.14) <0.01 - - 2.89 (1.29 - 6.46) 0.01 - - 
Total dose 1.09 (1.05 - 1.14) <0.01 1.07 (1.02 - 1.13) 0.01 - - 1.10 (1.02 - 1.17) 0.01 
Diabetes - - 4.00 (1.42 - 11.27) 0.01 - - - - 
D25 1.03 (1.00-1.06) 0.04 -  - - - - 
Dmax 1.10 (1.04-1.17) <0.01 -  - - - - 
Age 1.06 (1.01-1.11) 0.02 -  - - - - 
 
 
CI: confidence interval, RR: relative risk, p value ! 0.05 was considered statistically significant. D25: minimal dose received in 25% 
of the bladder wall volume. 
Following parameters have been tested in the model: age, diabetes, anticoagulant treatment, prior abdominal surgery, prior 
transurethral resection of prostate, hypertension, coronary insufficiency, gleason score, T stage, prognostic group of risk (D'amico), 
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RT technique (2D, Conformational 3D with or without IMRT/IGRT), total dose and fractionation, target volume, dose received by the 
bladder (maximal dose, D25, D50), and androgen deprivation. 
